Sage Therapeutics' financials indicate a need for additional funding in 2025, risking dilution and further financial ...

Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE – Get Free Report) have been assigned a consensus rating of “Hold” from the ...

It was an extremely busy week in the biotech sector, with several companies making important presentations at the J.P. Morgan ...

Key Takeaways Sage Therapeutics reported that Biogen made an unsolicited offer to purchase all of the shares of the ...

SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in providing solutions to brain health medicines. It focuses on diseases and disorders of the brain. Its products include ...

Sage Therapeutics reviews Biogen's $7.22 per share acquisition proposal amid ongoing restructuring and focus on Zurzuvae for postpartum depression.

Sage Therapeutics, Inc. (Nasdaq: SAGE) saw its stock price soar by an impressive 33.87%, reaching $7.43 during Monday’s premarket trading session. The surge came on the heels of the company’s ...

In a report released today, Joon Lee from Truist Financial maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report). The ...

Sage Therapeutics Inc is a clinical-stage biopharmaceutical ... receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults ...

RBC Capital Mkts has recently raised SAGE Therapeutics Inc (SAGE) stock to Sector Perform rating, as announced on November 21, 2024, according to Finviz. Earlier, on October 10, 2024, Raymond James ...

Analysts fell to the sidelines weighing in on Halozyme (HALO – Research Report) and SAGE Therapeutics (SAGE – Research Report) with neutral ...